Curriculum and Training

 

Rotations

  • Radiation/Oncology
  • Coagulation
  • Hematopathology
  • Research
  • Blood bank
  • Hematopathology
  • St. Jude Children's Hospital
  • Research Months (2)
  • Hemophilia
  • Palliative Care
  • Breast
  • Gyn/Onc
  • Research

Many other elective opportunities are available including bone marrow transplant depending on the interest of the fellow. Outside rotations are offered and are at the discretion of the program director and the university. Research months are designed to allow the fellow to develop his/her interest. Up to 18 months can be available for protected research time.

First Year Second Year Third Year
Malignant Heme 2 1-2 0
Oncology Service 2 1-2 0
VA Consults 2 1-2 0
MED Consults 2 1-2 0
MUH Consults 1 2 1
BM Transplant 0-1 0-1 0
Coagulation 1 0 0
Hemophilia 0-1 0-1 0
St. Jude 0 1 0
Rad. Onc 1 0 0
Hematopathology 1 0-1 0
Blood Bank 0 1 0
Breast 0 0-1 1-2
Gyn/Onc 0 0 1
Palliative Care 0 0 1
Electives/Research 0-1 3-4 9-10

Didactics

  • Radiation/Oncology
  • Coagulation
  • Hematopathology
  • Research
  • Blood bank
  • Hematopathology
  • St. Jude Children's Hospital
  • Research Months (2)
  • Hemophilia
  • Palliative Care
  • Breast
  • Gyn/Onc
  • Research

Many other elective opportunities are available including bone marrow transplant depending on the interest of the fellow. Outside rotations are offered and are at the discretion of the program director and the university. Research months are designed to allow the fellow to develop his/her interest. Up to 18 months can be available for protected research time.

First Year Second Year Third Year
Malignant Heme 2 1-2 0
Oncology Service 2 1-2 0
VA Consults 2 1-2 0
MED Consults 2 1-2 0
MUH Consults 1 2 1
BM Transplant 0-1 0-1 0
Coagulation 1 0 0
Hemophilia 0-1 0-1 0
St. Jude 0 1 0
Rad. Onc 1 0 0
Hematopathology 1 0-1 0
Blood Bank 0 1 0
Breast 0 0-1 1-2
Gyn/Onc 0 0 1
Palliative Care 0 0 1
Electives/Research 0-1 3-4 9-10

Conferences

Education is our top priority at the University of Tennessee. As such, we offer multiple educational experiences, including:

  • An 18 month rotating, structured curriculum, covering all of the major topics in Hematology / Oncology Monday & Tuesday morning conferences.
  • A Written curriculum for each rotation.
  • Exam review course - an annual review of hematology & oncology in preparation for in-service exams.
  • Journal Club- a once-monthly critical review of recent medical literature given by selected fellows.
  • Research Meetings – Once a month presentation of unusual or interesting cases by selected fellows.
  • Med/Onc Meetings – Once a month update of research and diseases presented by West Clinic physicians.
  • Foundational Conference – weekly for first year fellows, to build a base of knowledge to carry them forward in the program. The intent is to review each disease site in detail to prepare the first year fellow for their future clinical rotations, their second year fellowship and their in-service examination.
  • Board Review – weekly review for 3rd year fellows as a study guide for board certification.
  • Benign Hematology Symposium – meets monthly to discuss in-depth diagnosis and management of bleeding disorders.

Research Opportunities

Fellows are expected to complete a minimum of one research project, leading to abstract publication, or develop a full IRB approved protocol during their training. Research efforts will vary a great deal depending on the fellow from a very few months up to 18 months dedicated time, depending on interest and funding.

Fellows will choose a mentor early in their first year and learn research methodology in practical ways by developing and pursuing a project of interest. Large patient data banks are available to review questions of interest. Our program is linked with a multi-institutional national research network (ACORN) which provides the opportunity to design investigator initiated clinical trials. The University of Tennessee and St Jude’s research hospital provide pathways toward bench and translational research as well.

Cancer Research Center

Below are listed some of the abstracts and publications our most recent fellows have completed during their time in the program:

Publications

Mansoor Haq
QI Project -Improving referral and transfer of information from in-patient setting to out-patient clinic at the Regional Medical Center

Grant Project - "Toxicity and outcomes in African-American and Caucasian patients with adjuvant/neo-adjuvant chemotherapy for breast cancer." Dr. Lee Schwartzberg, M.D., Dr. Pranitha Naini, M.D., Dr. Jessica Snider, D.O., and Dr. Mansoor Ul Haq, M.D.

Bojia Li
Research Grant "Sipuleucel in men with metastatic castration resistant prostate cancer" Dr. Brad Somer, M.D., and Dr. Bojia Li, M.D.

Obiageli Ogbata
QI project - Drug Utilization evaluation of erythropoietin pre and post APPRISE

Research Grant "Identification of micro-RNA (miRllA) genomic profiling and its potential use in predicting outcome and response to chemotherapy in muscle invasive transitional cell bladder cancer." Dr. Daruka Mahadevan, M.D., and Obiageli Ogbata, MD

Real World Symptom Burden and Early Treatment Discontinuation in 1st Line Metastatic Breast Cancer Authors: Mark S. Walker, PhD1, Anthony S. Masaquel, PhD, MPH2, Jiandong Kerr, MS1, Deepa Lalla, PhD2 Daejin Abidoye, MD, MPH,2 Obiageli Ogbata, MD,3 Lee S. Schwartzberg, MD3, Poster Presentation: ASCO 2013

Manjari Pandey
Research Grant "Molecular Hallmarks of Transformed Follicular Lymphoma" Dr. Daruka Mahadevan, M.D., and Dr. Manjari Pandey, M.D.

Jashmin Patel
Research Grant "Hydrocytolytic Peritoneal Lavage in Ovarian Cancer" Joseph Santoso, M.D., Lawrence Pfeffer, PhD, and Jashmin K. Patel, M.D.

Gregg Sutton
Phase Ib Study to evaluate safety, tolerability and efficacy R1507 a monoclonal antibody to IGF- 1R in combination with multiple standard chemotherapy regimens in patients with advanced solid malignancies. Mahadevan D, Sutton G, Arteta-Bulos R, Miller P, Swart R, Walker M, Munster P, Dees C, Haluska P, Maitland M, Marshall J, Hamid O and Kurzrock R [ASCO Abstract 2013]

Andrew Fintel

Social connectivity and outcomes for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). 

Influence of Insurance and Marital Status on Outcomes of Adolescents and Young Adults With Acute Lymphoblastic Leukemia.

Benny Johnson

Molecular profiling of a case of advanced pancreatic cancer identifies an active and tolerable combination of targeted therapy with backbone chemotherapy.

Emerging Role and Targeting of Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) in Human Malignancies. 

Novel mutational and pathway signatures in relapsed/refractory colorectal cancer patients.

Co-morbidities Drive Outcomes for Both Malignancy-Associated and Non-Malignancy-Associated Hemophagocytic Syndrome 

Under-Recognition of Hemophagocytic Lymphohistiocytosis in United States' Rural, Non-Teaching Hospitals

Secondary Hemophagocytic Lymphohistiocytosis (SHLH) in the Context of Newly Diagnosed Philadelphia Positive, CD 20+ B-Cell Acute Lymphoblastic Lymphoma (B-ALL): A Case Report and Brief Review of Literature.

Secondary acute lymphoblastic leukemia is an independent predictor of poor prognosis. 

Dual Inhibition of the Androgen Receptor & PI3K/mTOR Pathways has significant anti-tumor activity in Castration-Resistant Prostate Cancer.

Bojia Li

Research Grant "Sipuleucel in men with metastatic castration resistant prostate cancer" Dr. Brad Somer, M.D., and Dr. Bojia Li, M.D.

Manjari Pandey

Research Grant "Molecular Hallmarks of Transformed Follicular Lymphoma" Dr. Daruka Mahadevan, M.D., and Dr. Manjari Pandey, M.D.

Jashmin Patel

Research Grant "Hydrocytolytic Peritoneal Lavage in Ovarian Cancer" Joseph Santoso, M.D., Lawrence Pfeffer, PhD, and Jashmin K. Patel, M.D.

Gregg Sutton

Phase Ib Study to evaluate safety, tolerability and efficacy R1507 a monoclonal antibody to IGF- 1R in combination with multiple standard chemotherapy regimens in patients with advanced solid malignancies. Mahadevan D, Sutton G, Arteta-Bulos R, Miller P, Swart R, Walker M, Munster P, Dees C, Haluska P, Maitland M, Marshall J, Hamid O and Kurzrock R [ASCO Abstract 2013]

Eric Wiedower

Unusual spontaneous aneursym formation in a patient being treated w/ibrutinib for chronic lymphoma leukemia.

Comorbidities drive outcomes for both maligancy and non-malignancy assoicated hemophagocytic syndrome.

Addition of rituximab to chemotherapy decreased mortality rates of primary surgery for gastric DLBCL without increasing early mortality.

Under recognition of hemophagocytic lymphohistiocytosis in US rural non-teaching hospitals.

Induction of AML with idarubicin, cytarabine, and cladribine

George Yaghmour

Age and population-based mortality rate (EMR) in Acute Myeloid Leukemia (AML) vs the EMR reported by SWOG.

All that glitters is not gold: differential diagnosis of clover-leaf lymphocytes.

Training Sites/Clinics

All fellows are assigned to a continuity care clinic at the VA or the West Clinic. Each first and second year fellow has a continuity clinic for one half day each week at the VA. Patients are longitudinal, managed care, post-hospital follow-ups, consultations, or walk-in primary care patients. First-hand knowledge is gained about managed health care. Each fellow has an extraordinary amount of patient contact. Second and Third year fellows will also have one half day clinic at West Clinic in addition to the VA clinic.

Call and Moonlighting

Fellows currently take home call for one week at a time. Call is split between second and third year fellows. The average amount of call is 8 weeks per year. The fellow on malignant heme service takes malignant heme home call Monday through Thursday night. Hematology/Oncology fellows do not take in house call.

Moonlighting opportunities are available and are at the discretion of the program director and must be in compliance with ACGME duty hour restrictions.

Contact Us

Division of Hematology & Oncology

Site contact:
Janet Herriman
Residency Coordinator
956 Court St.  Suite H310A
Coleman Building
Memphis, TN  38163
901-448-5733

A division of the
Dept of Internal Medicine